Cargando…

Modified Gold Nanoparticles to Overcome the Chemoresistance to Gemcitabine in Mutant p53 Cancer Cells

Mutant p53 proteins result from missense mutations in the TP53 gene, the most mutated in human cancer, and have been described to contribute to cancer initiation and progression. Therapeutic strategies for targeting mutant p53 proteins in cancer cells are limited and have proved unsuitable for clini...

Descripción completa

Detalles Bibliográficos
Autores principales:	García-Garrido, Eduardo, Cordani, Marco, Somoza, Álvaro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703659/ https://www.ncbi.nlm.nih.gov/pubmed/34959348 http://dx.doi.org/10.3390/pharmaceutics13122067

Ejemplares similares

MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
por: Dhayat, Sameer A., et al.
Publicado: (2015)

Targeting autophagy using metallic nanoparticles: a promising strategy for cancer treatment
por: Cordani, Marco, et al.
Publicado: (2018)

Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles
por: Chen, Zhe, et al.
Publicado: (2018)

Lauric Acid Overcomes Hypoxia-Induced Gemcitabine Chemoresistance in Pancreatic Ductal Adenocarcinoma
por: Takagi, Tadataka, et al.
Publicado: (2023)

Attempts to remodel the pathways of gemcitabine metabolism: Recent approaches to overcoming tumours with acquired chemoresistance
por: Saiki, Yuriko, et al.
Publicado: (2020)

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells
por: Cordani, Marco, et al.
Publicado: (2020)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Lapatinib Suppresses HER2-Overexpressed Cholangiocarcinoma and Overcomes ABCB1– Mediated Gemcitabine Chemoresistance
por: Bai, Zhiqing, et al.
Publicado: (2022)

Pancreatic Cancer Chemoresistance to Gemcitabine
por: Amrutkar, Manoj, et al.
Publicado: (2017)

Targeting P53 as a Future Strategy to Overcome Gemcitabine Resistance in Biliary Tract Cancers
por: Wu, Chiao-En, et al.
Publicado: (2020)

BAG2 drives chemoresistance of breast cancer by exacerbating mutant p53 aggregate
por: Huang, Xinjian, et al.
Publicado: (2023)

Nanomaterials as Inhibitors of Epithelial Mesenchymal Transition in Cancer Treatment
por: Cordani, Marco, et al.
Publicado: (2019)

Albumin-Based Nanoparticles for the Delivery of Doxorubicin in Breast Cancer
por: Prajapati, Rama, et al.
Publicado: (2021)

Gold Nanoparticles sensitize pancreatic cancer cells to gemcitabine
por: Huai, Yanyan, et al.
Publicado: (2019)

Mutant p53 promotes RCP-dependent chemoresistance coinciding with increased delivery of P-glycoprotein to the plasma membrane
por: Phatak, Vinaya, et al.
Publicado: (2021)

Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2
por: Tung, Min-Che, et al.
Publicado: (2015)

Wild-type p53 oligomerizes more efficiently than p53 hot-spot mutants and overcomes mutant p53 gain-of-function via a “dominant-positive” mechanism
por: Walerych, Dawid, et al.
Publicado: (2018)

Smart Modification on Magnetic Nanoparticles Dramatically Enhances Their Therapeutic Properties
por: Lafuente-Gómez, Nuria, et al.
Publicado: (2021)

Editorial: Novel Cancer Treatments Based on Autophagy Modulation
por: Cordani, Marco, et al.
Publicado: (2021)

The Fhit protein: an opportunity to overcome chemoresistance
por: Gaudio, Eugenio, et al.
Publicado: (2016)

Cisplatin for cancer therapy and overcoming chemoresistance
por: Ranasinghe, Ranmali, et al.
Publicado: (2022)

Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma
por: Okuno, Keisuke, et al.
Publicado: (2022)

Overcoming Chemoresistance: Altering pH of Cellular Compartments by Chloroquine and Hydroxychloroquine
por: Halcrow, Peter W., et al.
Publicado: (2021)

Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
por: Nakano, Y, et al.
Publicado: (2007)

Reversing chemoresistance of malignant glioma stem cells using gold nanoparticles
por: Orza, Anamaria, et al.
Publicado: (2013)

Cancer-derived p53 mutants suppress p53-target gene expression—potential mechanism for gain of function of mutant p53
por: Vikhanskaya, Faina, et al.
Publicado: (2007)

RGDV-modified gemcitabine: a nano-medicine capable of prolonging half-life, overcoming resistance and eliminating bone marrow toxicity of gemcitabine
por: Liu, Wenchao, et al.
Publicado: (2019)

Ets-1 expression and gemcitabine chemoresistance in pancreatic cancer cells
por: Khanna, Amit, et al.
Publicado: (2010)

Targeting Cancer Stem Cells to Overcome Chemoresistance
por: Nunes, Toni, et al.
Publicado: (2018)

Disrupting the endothelin and Wnt relationship to overcome chemoresistance
por: Rosanò, Laura, et al.
Publicado: (2015)

Overcoming Chemoresistance via Extracellular Vesicle Inhibition
por: Hayatudin, Raeesah, et al.
Publicado: (2021)

Editorial: Strategies in overcoming the chemoresistance in colorectal cancer
por: Vodenkova, Sona, et al.
Publicado: (2023)

Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells
por: van Oosterwijk, J G, et al.
Publicado: (2013)

Association of Loss of Heterozygosity at the p53 Locus with Chemoresistance in Osteosarcomas
por: Goto, Akiteru, et al.
Publicado: (1998)

p53 Signaling on Microenvironment and Its Contribution to Tissue Chemoresistance
por: Souza, Leonel Cardozo de Menezes e, et al.
Publicado: (2022)

Nutlin-3 overcomes arsenic trioxide resistance and tumor metastasis mediated by mutant p53 in Hepatocellular Carcinoma
por: Zheng, Tongsen, et al.
Publicado: (2014)

Combining β-Carotene with 5-FU via Polymeric Nanoparticles as a Novel Therapeutic Strategy to Overcome uL3-Mediated Chemoresistance in p53-Deleted Colorectal Cancer Cells
por: Carotenuto, Pietro, et al.
Publicado: (2023)

A novel mutant p53 binding partner BAG5 stabilizes mutant p53 and promotes mutant p53 GOFs in tumorigenesis
por: Yue, Xuetian, et al.
Publicado: (2016)

Editorial: New Approaches to Tackle EMT and Fibrosis: From Epigenetics to Nanotechnology
por: Battistelli, Cecilia, et al.
Publicado: (2021)

Potential Role of Exosomes in the Chemoresistance to Gemcitabine and Nab-Paclitaxel in Pancreatic Cancer
por: Comandatore, Annalisa, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6btk3gqnv2518o24dkrrqvg6ce